TERN - CIK 0001831363
Terns Pharmaceuticals, Inc. trades as TERN and has a market capitalization of $6.12 B, making it the #1250 largest US-listed company by market value. In its fiscal 2022 annual report the company posted revenue of $0.00, down 100.0% from the prior year and net income of -$96.21M. This page tracks Terns Pharmaceuticals, Inc. through 430 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| 15-12G | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-13 |
| EFFECT | - | 2026-05-07 |
| Insider trade | 4 | 2026-05-05 |
| Insider trade | 4 | 2026-05-05 |
| Insider trade | 4 | 2026-05-05 |
| Insider trade | 4 | 2026-05-05 |
| Insider trade | 4 | 2026-05-05 |
Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia — Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) — Terns Pharmaceuticals, Inc.
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML) — Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences — Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) — Terns Pharmaceuticals, Inc.
The largest companies sharing Terns Pharmaceuticals, Inc.'s SEC industry classification (pharmaceutical preparations).
Terns Pharmaceuticals, Inc. (TERN) has a market capitalization of $6.12 B as of 2026-06-10, ranking #1250 among US-listed companies.
Terns Pharmaceuticals, Inc. reported revenue of $0.00 for fiscal year 2022, a decrease of 100.0% year over year.
In its latest fiscal year Terns Pharmaceuticals, Inc. reported a net loss of $96.21M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.